Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23478546 | 0.93 | HRH4 (0.34) | DPP4HDAC1NR1H2NR1H3MAP4K4 | |
| SCHEMBL20424245 | 0.81 | ABCB1 (0.33) | HRH4 | |
| SCHEMBL21796860 | 0.77 | CKS1B (0.47) | MAP4K4SUV39H2HRH4GPR119 | |
| SCHEMBL23478543 | 0.75 | LRRK2 (0.54) | DPP4 | |
| SCHEMBL23478573 | 0.68 | PRKCQ (0.35) | HDAC1SUV39H2HRH4 | |
| SCHEMBL8512175 | 0.67 | HDAC1 (0.41) | DPP4HDAC1NR1H2NR1H3MAP4K4 | |
| SCHEMBL8512178 | 0.67 | HDAC1 (0.41) | DPP4HDAC1NR1H2NR1H3MAP4K4 | |
| SCHEMBL38666731 | 0.67 | HDAC1 (0.41) | DPP4HDAC1NR1H2NR1H3MAP4K4 | |
| SCHEMBL38666138 | 0.67 | HDAC1 (0.41) | DPP4HDAC1NR1H2NR1H3MAP4K4 | |
| SCHEMBL38666106 | 0.66 | HDAC1 (0.40) | DPP4HDAC1NR1H2NR1H3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | LRRK2, BRSK2, MAPKAPK2 | DPP4 3017/4885HDAC1 690/4885NR1H2 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.